Herpes simplex virus encephalitis during treatment with etanercept

Crusio, Robbert; Singson, Stephanie V; Haroun, Faysal; Mehta, Hetal H.; Parenti, David M.

doi:10.3109/00365548.2013.849816

Cited by 13 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient was successfully treated with a combination of acyclovir and foscarnet. A patient receiving etanercept (i.e., a fusion protein made of the extracellular domain of human TNF receptor 2 and the Fc end of human IgG 1 ) developed HSE (173). MRI scans showed lesions in the right fronto-temporoparietal region with the presence of edema.…”

Section: Occurrence Of Hse After Immunomodulatory Therapymentioning

confidence: 99%

Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis

Piret

Boivin

2020

Clin Microbiol Rev

View full text Add to dashboard Cite

SUMMARY Herpes simplex virus 1 (HSV-1) can be responsible for life-threatening HSV encephalitis (HSE). The mortality rate of patients with HSE who do not receive antiviral treatment is 70%, with most survivors suffering from permanent neurological sequelae. The use of intravenous acyclovir together with improved diagnostic technologies such as PCR and magnetic resonance imaging has resulted in a reduction in the mortality rate to close to 20%. However, 70% of surviving patients still do not recover complete neurological functions. Thus, there is an urgent need to develop more effective treatments for a better clinical outcome. It is well recognized that cerebral damage resulting from HSE is caused by viral replication together with an overzealous inflammatory response. Both of these processes constitute potential targets for the development of innovative therapies against HSE. In this review, we discuss recent progress in therapy that may be used to ameliorate the outcome of patients with HSE, with a particular emphasis on immunomodulatory agents. Ideally, the administration of adjunctive immunomodulatory drugs should be initiated during the rise of the inflammatory response, and its duration should be limited in time to reduce undesired effects. This critical time frame should be optimized by the identification of reliable biomarkers of inflammation.

show abstract

Section: Occurrence Of Hse After Immunomodulatory Therapymentioning

confidence: 99%

Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis

Piret

Boivin

2020

Clin Microbiol Rev

View full text Add to dashboard Cite

show abstract

“…Herpes encephalitis in immunocompromised patients, mainly in relation to TNF-alpha inhibitors such as infliximab, is reported in the literature in some case reports [ 5 , 6 , 7 ]. Among these, 5 cases are described of patients with TNF-alpha inhibitor therapy and herpes encephalitis.…”

Section: Discussionmentioning

confidence: 99%

Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment

Montfort

Loos

Anten³

et al. 2017

Case Rep Oncol

View full text Add to dashboard Cite

Until a few years ago, metastatic melanoma had a poor prognosis with limited treatment options. These therapeutics options and thereby median survival have increased obviously over 5 years with the arrival of immunotherapeutic drugs like ipilimumab, nivolumab, and pembrolizumab. Nowadays, ipilimumab is often used in patients with metastatic melanoma. In this paper, we report a case of a 68-year-old man who developed, and eventually died of, herpes encephalitis after introducing ipilimumab as treatment for metastatic melanoma. To our knowledge, this is the first report in which herpes encephalitis as a complication after ipilimumab and infliximab treatment is described and we would like to make physicians aware of this possible serious neurological complication, especially when a patient has a history of herpes simplex infection.

show abstract

“…It has been shown that the Th1/Th17 cells in the periphery of RA patients are reduced, and Tregs are significantly increased after rhTNFR:Fc therapy [ 32 ]. In recent years, there have been many documents reported the multiple side effects accompanied with anti-TNF-α therapies, such as the increased risk of severe viral and bacterium infection [ 33 , 34 ], anaphylaxis [ 35 ], and tumor [ 36 ]. Additionally, their considerable costs still limit their widespread utilization.…”

Section: Discussionmentioning

confidence: 99%

Anti-Inflammatory Effects of Recombinant Human PDCD5 (rhPDCD5) in a Rat Collagen-Induced Model of Arthritis

Xiao

et al. 2014

Inflammation

View full text Add to dashboard Cite

Programmed cell death 5 (PDCD5) was first identified as a gene upregulated in cells undergoing apoptosis. We recently demonstrated the inhibitory effect of PDCD5 on experimentally induced autoimmune encephalomyelitis. In this study, we investigated the anti-inflammatory effects of recombinant human PDCD5 (rhPDCD5) in a rat collagen-induced arthritis (CIA) model. We find that vaccination of collagen II (CII) induced CIA rats with rhPDCD5 significantly delayed the occurrence and reduced the severity of CIA rats. rhPDCD5 also restored the loss of Foxp3+ regulatory T (Treg) cells and decreased the population of Th1 and Th17 in CIA rats. Simultaneously, rhPDCD5 treatment suppressed the production of pro-inflammatory cytokines (interleukin (IL)-6, IL-17A, tumor necrosis factor-α (TNF-α), and interferon gamma (IFN-γ)) and increased the secretion of anti-inflammatory cytokines (transforming growth factor beta 1 (TGF-β1) and IL-10) in CIA rats. In addition, rhPDCD5 inhibited the ability of CII to induce proliferation of splenocytes and lymph node cells (LNCs) and promoted the CII-activated CD4+ cell apoptosis. These results of rhPDCD5-treated CIA rats were similar with those of recombinant human TNF-α receptor IgG Fc (rhTNFR:Fc). Thus, to our knowledge, we provide the first evidence that rhPDCD5 may be an efficient approach to diminishing exacerbated immune responses in CIA, indicating its therapeutic potential in the treatment of rheumatoid arthritis and other autoimmune diseases.

show abstract

Herpes simplex virus encephalitis during treatment with etanercept

Cited by 13 publications

References 10 publications

Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis

Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis

Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment

Anti-Inflammatory Effects of Recombinant Human PDCD5 (rhPDCD5) in a Rat Collagen-Induced Model of Arthritis

Contact Info

Product

Resources

About